Skip to main content
Caplight Logo









BLEEDnFIRE Therapeutics

BLEEDnFIRE Therapeutics

Private
BernHealthcare & Life Scienceshttps://bleednfire-tx.com/

Last Round

Grant

May 27, 2026

Total Funding Raised

$170,000

Momentum

Top 50%

of companies Caplight tracks

Company Overview

BLEEDnFIRE Therapeutics is a biotechnology company developing first-in-class RNA-based therapies for rare bleeding disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

RNA therapeuticssiRNArare bleeding disordersbiotech startupRNAi platformcoagulation therapyGalNAc-conjugatedProtein Shemophilia treatmentdrug developmentsubcutaneous dosingRNA medicinepreclinical biotechrare disease drug

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BLEEDnFIRE Therapeutics Comparables

Compare BLEEDnFIRE Therapeutics with similar companies based on industry and business-model similarity.

BLEEDnFIRE Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Eli Lilly and Company
72%
Hemab Therapeutics
70%
Sanofi
69%

BLEEDnFIRE Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 27, 2026
GrantNov 29, 2024

BLEEDnFIRE Therapeutics Investors

Notable investors and investment history

BLEEDnFIRE Therapeutics investors
InvestorRounds
Gebert Rüf StiftungGrant
KickfundGrant
InnosuisseGrant
Venture KickGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 27, 2026

    Received funding from Kickfund, Gebert Rüf Stiftung, Innosuisse, and Venture Kick.

  • Nov 29, 2024

    $170K grant received from Venture Kick.

BLEEDnFIRE Therapeutics Filings

Explore SEC and related filing metadata, where available.

BLEEDnFIRE Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about BLEEDnFIRE Therapeutics's valuation, stock price, and market status.

Is BLEEDnFIRE Therapeutics a public or private company?

BLEEDnFIRE Therapeutics is a private company.

What is the current stock price of BLEEDnFIRE Therapeutics?

BLEEDnFIRE Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is BLEEDnFIRE Therapeutics worth (valuation)?

Valuation information for BLEEDnFIRE Therapeutics is not publicly available.

Can I buy BLEEDnFIRE Therapeutics stock?

BLEEDnFIRE Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was BLEEDnFIRE Therapeutics's last funding round?

BLEEDnFIRE Therapeutics's most recent funding round was Grant on May 27, 2026.

Who are the main investors in BLEEDnFIRE Therapeutics?

Key investors in BLEEDnFIRE Therapeutics include Gebert Rüf Stiftung, Kickfund, Innosuisse, Venture Kick.

Will BLEEDnFIRE Therapeutics IPO soon?

No public IPO plans have been announced for BLEEDnFIRE Therapeutics.

How can I track BLEEDnFIRE Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor BLEEDnFIRE Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBern
Year Founded2025
Last FundingMay 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?